PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Molecular and clinical attributes of uterine leiomyomas.

Abstract Uterine leiomyomas, also called uterine fibroids or myomas, represent one of the most common benign tumour types in women of a fertile age. Leiomyomas arise due to transformation of the layer of smooth muscle cells of corpus uteri - the myometrium. Despite frequent occurrence of this disease, the molecular mechanisms behind the origin and development of leiomyomas are still relatively unknown. Most predisposed are obese women and women of African origin. In more than half of cases, leiomyomas remain asymptomatic. Genetic factors also have an important impact on the development of these hormone-dependent tumours. However, the clinical and molecular characteristics of familiar and sporadic leiomyomas can widely differ. The main reason is the heterogeneity of this disease and the abundance of factors which can underlie their tumourigenesis. Clinical diagnosis of uterine leiomyomas without surgical interference can be hindered in the case of small, mostly submucosal leiomyomas or if it is necessary to avoid potential malignancy of tumour. Also, medical treatment of uterine leiomyomas cannot be nowadays considered sufficient with many medical agents still being tested only within clinical research. The main goal of this article is to summarise known facts about the aetiology of leiomyomas, risk factors that contribute to their development, known molecular-genetic aberrations connected with the presence of leiomyomas as well as the possibilities of their diagnosis and treatment.
PMID
Related Publications

Leiomyomas of the uterine body: Molecular-genetical aspects of formation and development.

The management of uterine leiomyomas.

Stem cells and uterine leiomyomas: What is the evidence?

The management of uterine leiomyomas.

Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth.

Authors

Mayor MeshTerms
Keywords

Leiomyomas

fibroids

growth factors

mesenchymal tumours

oestrogen

uterus

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28653894
OWN - NLM
STAT- In-Process
DA  - 20170627
LR  - 20170627
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - Molecular and clinical attributes of uterine leiomyomas.
PG  - 1010428317710226
LID - 10.1177/1010428317710226 [doi]
AB  - Uterine leiomyomas, also called uterine fibroids or myomas, represent one of the 
      most common benign tumour types in women of a fertile age. Leiomyomas arise due
      to transformation of the layer of smooth muscle cells of corpus uteri - the
      myometrium. Despite frequent occurrence of this disease, the molecular mechanisms
      behind the origin and development of leiomyomas are still relatively unknown.
      Most predisposed are obese women and women of African origin. In more than half
      of cases, leiomyomas remain asymptomatic. Genetic factors also have an important 
      impact on the development of these hormone-dependent tumours. However, the
      clinical and molecular characteristics of familiar and sporadic leiomyomas can
      widely differ. The main reason is the heterogeneity of this disease and the
      abundance of factors which can underlie their tumourigenesis. Clinical diagnosis 
      of uterine leiomyomas without surgical interference can be hindered in the case
      of small, mostly submucosal leiomyomas or if it is necessary to avoid potential
      malignancy of tumour. Also, medical treatment of uterine leiomyomas cannot be
      nowadays considered sufficient with many medical agents still being tested only
      within clinical research. The main goal of this article is to summarise known
      facts about the aetiology of leiomyomas, risk factors that contribute to their
      development, known molecular-genetic aberrations connected with the presence of
      leiomyomas as well as the possibilities of their diagnosis and treatment.
FAU - Dvorska, Dana
AU  - Dvorska D
AD  - 1 Division of Molecular Medicine, Biomedical Center Martin, Jessenius Faculty of 
      Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia.
AD  - 2 Clinic of Gynecology and Obstetrics, Jessenius Faculty of Medicine in Martin,
      Comenius University in Bratislava, Martin, Slovakia.
FAU - Brany, Dusan
AU  - Brany D
AD  - 1 Division of Molecular Medicine, Biomedical Center Martin, Jessenius Faculty of 
      Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia.
AD  - 2 Clinic of Gynecology and Obstetrics, Jessenius Faculty of Medicine in Martin,
      Comenius University in Bratislava, Martin, Slovakia.
FAU - Dankova, Zuzana
AU  - Dankova Z
AD  - 3 Division of Oncology, Biomedical Center Martin, Jessenius Faculty of Medicine
      in Martin, Comenius University in Bratislava, Martin, Slovakia.
FAU - Halasova, Erika
AU  - Halasova E
AD  - 1 Division of Molecular Medicine, Biomedical Center Martin, Jessenius Faculty of 
      Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia.
FAU - Visnovsky, Jozef
AU  - Visnovsky J
AD  - 2 Clinic of Gynecology and Obstetrics, Jessenius Faculty of Medicine in Martin,
      Comenius University in Bratislava, Martin, Slovakia.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
OTO - NOTNLM
OT  - Leiomyomas
OT  - fibroids
OT  - growth factors
OT  - mesenchymal tumours
OT  - oestrogen
OT  - uterus
EDAT- 2017/06/28 06:00
MHDA- 2017/06/28 06:00
CRDT- 2017/06/28 06:00
AID - 10.1177/1010428317710226 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jun;39(6):1010428317710226. doi: 10.1177/1010428317710226.